SUMMARY
Recently, we demonstrated that RPL5 and RPL11 act in a mutually dependent
manner to inhibit Hdm2 and stabilize p53 following impaired ribosome biogenesis.
Given that RPL5 and RPL11 form a preribosomal complex with noncoding 5S
ribosomal RNA (rRNA) and the three have been implicated in the p53 response, we
reasoned they may be part of an Hdm2-inhibitory complex. Here, we show that
small interfering RNAs directed against 5S rRNA have no effect on total or
nascent levels of the noncoding rRNA, though they prevent the reported Hdm4
inhibition of p53. To achieve efficient inhibition of 5S rRNA synthesis, we
targeted TFIIIA, a specific RNA polymerase III cofactor, which, like depletion
of either RPL5 or RPL11, did not induce p53. Instead, 5S rRNA acts in a
dependent manner with RPL5 and RPL11 to inhibit Hdm2 and stabilize p53.
Moreover, depletion of any one of the three components abolished the binding of
the other two to Hdm2, explaining their common dependence. Finally, we
demonstrate that the RPL5/RPL11/5S rRNA preribosomal complex is redirected from
assembly into nascent 60S ribosomes to Hdm2 inhibition as a consequence of
impaired ribosome biogenesis. Thus, the activation of the Hdm2-inhibitory
complex is not a passive but a regulated event, whose potential role in tumor
suppression has been recently noted.
Errors in ribosome biogenesis can result in quantitative or qualitative defects in protein synthesis and consequently lead to improper execution of the genetic program and the development of specific diseases. Evidence has accumulated over the last decade suggesting that perturbation of ribosome biogenesis triggers a p53-activating checkpoint signaling pathway, often referred to as the ribosome biogenesis stress checkpoint pathway. Although it was originally suggested that p53 has a prominent role in preventing diseases by monitoring the fidelity of ribosome biogenesis, recent work has demonstrated that p53 activation upon impairment of ribosome biogenesis also mediates pathological manifestations in humans. Perturbations of ribosome biogenesis can trigger a p53-dependent checkpoint signaling pathway independent of DNA damage and the tumor suppressor ARF through inhibitory interactions of specific ribosomal components with the p53 negative regulator, Mdm2. Here we review the recent advances made toward understanding of this newly-recognized checkpoint signaling pathway, its role in health and disease, and discuss possible future directions in this exciting research field. This article is part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
Cell growth is a prerequisite for cell proliferation, and ribosome biogenesis is a limiting factor for cell growth. In mammalian cells, the tumor suppressor p53 has been shown to induce cell-cycle arrest in response to impaired ribosome biogenesis. Recently, p53-independent mechanisms of cell-cycle arrest in response to alterations of ribosome biogenesis have been described. These findings provide a rational basis for the use of drugs that specifically impact ribosome biogenesis for the treatment of cancers lacking active p53 and extend the scenario of mechanisms involved in the relationship between cell growth and cell proliferation. Cancer Res; 72(7); 1602-7. Ó2012 AACR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.